Icon Plc $ICLR Stake Lessened by Neuberger Berman Group LLC

Neuberger Berman Group LLC cut its stake in Icon Plc (NASDAQ:ICLR) by 14.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,114 shares of the medical research company’s stock after selling 29,172 shares during the period. Neuberger Berman Group LLC owned 0.22% of Icon worth $31,246,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ICLR. Arvin Capital Management LP acquired a new position in Icon during the 3rd quarter worth $12,543,000. Nicholas Hoffman & Company LLC. raised its stake in shares of Icon by 24.3% in the 3rd quarter. Nicholas Hoffman & Company LLC. now owns 5,507 shares of the medical research company’s stock valued at $964,000 after purchasing an additional 1,077 shares in the last quarter. Keystone Investors PTE Ltd. bought a new position in shares of Icon during the third quarter worth about $5,867,000. Clifford Swan Investment Counsel LLC acquired a new position in Icon in the third quarter worth about $238,000. Finally, Westfield Capital Management Co. LP increased its holdings in Icon by 14.6% in the third quarter. Westfield Capital Management Co. LP now owns 396,354 shares of the medical research company’s stock valued at $69,362,000 after buying an additional 50,526 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

Icon Price Performance

Shares of NASDAQ ICLR opened at $107.20 on Friday. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The business’s fifty day moving average price is $152.10 and its two-hundred day moving average price is $167.96. The firm has a market capitalization of $8.66 billion, a PE ratio of 14.51, a P/E/G ratio of 2.75 and a beta of 1.35.

Wall Street Analyst Weigh In

ICLR has been the subject of several research reports. Truist Financial reiterated a “hold” rating and issued a $222.00 target price (down from $231.00) on shares of Icon in a research report on Thursday, January 8th. TD Cowen upgraded shares of Icon from a “hold” rating to a “buy” rating and lowered their target price for the company from $183.00 to $120.00 in a research note on Wednesday, February 18th. Leerink Partners reissued a “market perform” rating and set a $105.00 target price on shares of Icon in a report on Thursday, February 12th. Mizuho set a $216.00 price target on shares of Icon in a research report on Friday, January 9th. Finally, Barclays lifted their price target on shares of Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Six analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $157.47.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.